 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
26 News |  |
- || Lovaxin B (OST-HER2) / OS Therapies
Trial completion, Trial primary completion date: AOST-2121: Osteosarcoma Maintenance Therapy With OST31-164 (clinicaltrials.gov) - Sep 28, 2023
P2, N=39, Completed, Sponsor: George Clinical Pty Ltd
Recruiting --> Completed | Trial primary completion date: Apr 2023 --> Sep 2023
- ||| Lovaxin B (OST-HER2) / OS Therapies
Clinical: #OSTherapies Receives #RarePediatricDiseaseDesignation (RDD) in #Osteosarcoma for #OSTHER2 (#ListeriaMonocytogenes) https://t.co/ysJC1ey8ic (Twitter) - Nov 4, 2021
- || Lovaxin B (OST-HER2) / OS Therapies
Enrollment open: AOST-2121: Osteosarcoma Maintenance Therapy With OST31-164 (clinicaltrials.gov) - Oct 4, 2021
P2, N=45, Recruiting, Sponsor: George Clinical Pty Ltd
Recruiting --> Completed | Trial primary completion date: Apr 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- || Lovaxin B (OST-HER2) / OS Therapies
New P2 trial: AOST-2121: Osteosarcoma Maintenance Therapy With OST31-164 (clinicaltrials.gov) - Jul 22, 2021
P2, N=45, Not yet recruiting, Sponsor: George Clinical Pty Ltd
- || Lovaxin B (OST-HER2) / OS Therapies
#OSTherapies Acquires All Indications for #OSTHER2 (#ListeriaMonocytogenes) in #SolidTumors, Including Canines https://t.co/9lZcoSyEIa (Twitter) - Nov 18, 2020
- || Lovaxin B (OST-HER2) / OS Therapies
Trial completion, Trial completion date, Trial primary completion date: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors (clinicaltrials.gov) - Mar 5, 2019
P1b, N=12, Completed, Sponsor: Advaxis, Inc.
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Sep 2018 | Trial primary completion date: Aug 2018 --> Apr 2017 | Active, not recruiting --> Completed
- Lovaxin B (OST-HER2) / OS Therapies
Enrollment closed, Enrollment change: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors (clinicaltrials.gov) - Mar 15, 2018
P1b, N=12, Active, not recruiting, Sponsor: Advaxis, Inc.
Trial completion date: Dec 2018 --> Sep 2018 | Trial primary completion date: Aug 2018 --> Apr 2017 | Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=98 --> 12
- | Lovaxin B (OST-HER2) / OS Therapies
Phase classification: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors (clinicaltrials.gov) - Jul 27, 2016
P1b, N=98, Recruiting, Sponsor: Advaxis, Inc.
Recruiting --> Active, not recruiting | N=98 --> 12 Phase classification: P1/2 --> P1b
- |||| Lovaxin B (OST-HER2) / OS Therapies
Enrollment open: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors (clinicaltrials.gov) - Apr 14, 2016
P1/2, N=98, Recruiting, Sponsor: Advaxis, Inc.
Phase classification: P1/2 --> P1b Active, not recruiting --> Recruiting
- ||| Lovaxin B (OST-HER2) / OS Therapies
Enrollment closed, Trial primary completion date: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors (clinicaltrials.gov) - Feb 22, 2016
P1/2, N=98, Active, not recruiting, Sponsor: Advaxis, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2018 --> Aug 2018
- |||| Lovaxin B (OST-HER2) / OS Therapies
Enrollment open, Trial initiation date: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors (clinicaltrials.gov) - Oct 1, 2015
P1/2, N=98, Recruiting, Sponsor: Advaxis, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: May 2018 --> Aug 2018 Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Sep 2015
- ||||| Lovaxin B (OST-HER2) / OS Therapies
New P1/2 trial: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors (clinicaltrials.gov) - Mar 12, 2015
P1/2, N=98, Not yet recruiting, Sponsor: Advaxis, Inc.